期刊文献+

肺癌血清肿瘤标志物的临床意义 被引量:75

Clinical Utility of Serum Tumor Markers in Lung Cancer
下载PDF
导出
摘要 肺癌血清肿瘤标志物在肺癌的早期诊断、病理分型、疾病分期、疗效评估和指导预后等方面起着重要的作用,本文旨在对神经元特异性烯醇化酶(NSE)、胃泌素释放肽(ProGRP)、细胞角蛋白19片段(CYFRA21-1)、组织多肽抗原(TPA)、鳞状细胞癌相关抗原(SCC-Ag)和癌胚抗原(CEA)这6种重要的肺癌血清肿瘤标志物的临床意义进行综述。 Lung cancer shows a tendency of higher incidence and higher mortality in recent years,but the overall 5-year survival rate is less than 15%.Serum tumor markers of lung cancer play an important role in early diagnosis,determining of pathology types,staging,evaluation of response,and prognosis of lung cancer.In this review,6 most important markers were reviewed,including neuron-specific enolase(NSE),pro-gastrin-releasing peptide(ProGRP),cytokeratin 19 fragments(Cyfra 21-1) ,tissue polypeptide antigen(TPA),squamous cell carcinoma associated antigen(SCC-Ag),carcinoembryonic antigen(CEA).
作者 赵肖 王孟昭
出处 《中国肺癌杂志》 CAS 2011年第3期286-291,共6页 Chinese Journal of Lung Cancer
关键词 肺肿瘤 肿瘤标志物 诊断 治疗 Lung neoplasms Biological tumor marker Diagnosis Treatment
  • 相关文献

参考文献36

  • 1Chen WQ Zhang SW, Zou XN. Evaluation on the incidence, mortality and tendency of lung cancer in China. Thoracic Cancer~ 2010, 1 (1): 35-40.
  • 2Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 2008, 83(5):584-594.
  • 3Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med, 2005, 353(20): 2194-2195.
  • 4Hatzakis KD, Froudarakis ME, Bouros D, et al. Prognostic value of serum tumor markers in patients with lung cancer. Respiration, 2002, 69(1): 25-29.
  • 5Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med, 2007, 13(4): 249-255.
  • 6Molina R, Auge JM, Filella X, et al. Pro-gastrin-releasing peptide (proGRP) in patients with benign, and malignant diseases: comparison with CEA, SCC, CYFRA 21-1, and NSE in patients with lung cancer. Anticancer Res, 2005, 25(3): 1773-1778.
  • 7Schneider J, Philipp M, Velcovsky HG, et al. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA), and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res, 2003, 23(2): 885-893.
  • 8Shibayama T, Ueoka H, Nishi K, et al. Complementary roles of pro-gastrinreleasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small cell lung cancer (SCLC). Lung Cancer, 2001, 32(1): 61-69.
  • 9Niho S, Nishiwaki Y, Goto K, et al. Significance of serum pro-gastrinreleasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuronspecific enolase and carcinoembryonic antigen. Lung Cancer, 2000, 27(3): 159-167.
  • 10Okusaka T, Eguchi K, Kasai T. Serum levels of Pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res, 1997, 3(1): 123-127.

同被引文献743

引证文献75

二级引证文献650

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部